Abstract: A method performed by a User Equipment (UE) for handling a Non-Terrestrial Network (NTN) connection, includes: detecting at least one of: a presence of the UE in an NTN only coverage area, or a non-availability of a Terrestrial Network (TN) coverage at a location of the UE; determining an availability of an NTN; selecting the NTN for a registration of the UE; determining an absence of a voice-service support from the selected NTN, wherein the absence of the voice-service support indicates that the selected NTN does not support a voice service for the UE; performing at least one control action to avoid searching for the voice service during the registration of the UE on the NTN; and completing the registration of the UE on the NTN, based on the performed at least one control action.

Abstract: A method, performed by a user equipment (UE) camping on a serving cell in a non-terrestrial network (NTN), for provisioning cell selection or reselection in the NTN, includes: receiving, by the UE from the serving cell, a first message comprising a first set of information; receiving, by the UE, a second message comprising a second set of information broadcasted by the serving cell, wherein the second set of information comprises information that is at least partially different from the first set of information; generating, by the UE, a cell selection or reselection list based on the first set of information and the second set of information, wherein the cell selection or reselection list comprises a plurality of candidate cells; and performing, by the UE, at least one network cell selection or reselection operation based on the cell selection or reselection list.

Abstract: In an aspect of the present invention, a new active optic is provided, namely, a photo-magnetically actuated deformable mirror (PMADM) made of a magnetic composite structure and an optical quality substrate layer. The magnetic layer is composed of Polydimethylsiloxane (PDMS) and powdered ferromagnetic CrO2. A magnet may be used to deform the mirror surface. The powdered CrO2 has a low Curie temperature (preferably around 395 K) which allows changing the magnetization of the magnetic layer using a laser heating source, thus providing control over the deformation. In one embodiment, the structure has an overall dimension of 1.2 inch 1.2 inch 175 ?m with an optical pupil diameter of 8 mm. The PMADM is estimated to deform to a maximum stroke of 8.7731 ?m before failure with a 3 safety factor.

Abstract: Microbial enzymes are used for esterification of biomass-derived substrates for production of industrially valuable esters. E. coli was used as an efficient platform for recombinant synthesis of fusel lactates such as the green solvent ethyl lactate.

Abstract: The present invention discloses stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds comprising: a) a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients, b) at least one water-soluble seal coating over core c) at least one enteric coating layer over the seal coat wherein the core is free of a surfactant. The prior art discloses restrictive formulation techniques and suggests higher amounts of various excipients to achieve desired technical attributes. The prepared test formulations exhibited desired pharmaceutical technical attributes like drug release, assay, stability, no polymorphic change, reduced sticking to nasogastric and gastronomy tubes, and packaging material.

Abstract: The present invention discloses stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds comprising: a) a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients, b) at least one water-soluble seal coating over core c) at least one enteric coating layer over the seal coat wherein the core is free of a surfactant. The prior art discloses restrictive formulation techniques and suggests higher amounts of various excipients to achieve desired technical attributes. The prepared test formulations exhibited desired pharmaceutical technical attributes like drug release, assay, stability, no polymorphic change, reduced sticking to nasogastric and gastronomy tubes, and packaging material.

Abstract: The present invention discloses stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds comprising: a) a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients, b) at least one water-soluble seal coating over core c) at least one enteric coating layer over the seal coat wherein the said core comprises disintegrant (0-10%) and/or surfactant (0-2%) w/w of core. The prior art discloses restrictive formulation technique and suggest high amount of various excipients to achieve desired technical attributes. The prepared test formulations exhibited desired pharmaceutical technical attributes like drug release, assay, stability, no polymorphic change, reduced sticking to nasogastric and gastronomy tubes, and packaging material.

Abstract: The present invention discloses stable delayed release multiparticulate powder for oral suspension of proton pump inhibitor compounds comprising: a) a core with an effective amount of proton pump inhibitor and at least one or more pharmaceutical excipients, b) at least one water-soluble seal coating over core c) at least one enteric coating layer over the seal coat wherein the said core comprises disintegrant (0-10%) and/or surfactant (0-2%) w/w of core. The prior art discloses restrictive formulation technique and suggest high amount of various excipients to achieve desired technical attributes. The prepared test formulations exhibited desired pharmaceutical technical attributes like drug release, assay, stability, no polymorphic change, reduced sticking to nasogastric and gastronomy tubes, and packaging material.

Abstract: The present disclosure provides compositions comprising a hydrogel and a cell adhesion ligand that enhances the differentiation of mesenchymal stem cells into brown adipocytes, and/or enhances the maintenance of brown adipocytes. In some cases, a subject composition includes cells that are embedded within the hydrogel. The present disclosure also provides methods of making and using the subject compositions.

Abstract: Provided herein are hydrogel cell matrices, hydrogel cell matrix systems for the support, growth, and differentiation of a stem cell or progenitor cell and methods for making such hydrogel cell matrices.

Abstract: The present disclosure provides compositions comprising a hydrogel and a cell adhesion ligand that enhances the differentiation of mesenchymal stem cells into brown adipocytes, and/or enhances the maintenance of brown adipocytes. In some cases, a subject composition includes cells that are embedded within the hydrogel. The present disclosure also provides methods of making and using the subject compositions.

Abstract: Provided herein are hydrogel cell matrices, hydrogel cell matrix systems for the support, growth, and differentiation of a stem cell or progenitor cell and methods for making such hydrogel cell matrices.